Emergent BioSolutions-Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales

Emergent BioSolutions (EBS) reported an adjusted loss of 77 cents per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of 33 cents. In the year-ago quarter, EBS reported adjusted earnings of 11 cents per share.Revenues in the quarter totaled $276.6 million, down 16% from the prior-year period’s level. The reported figure outpaced the Zacks Consensus Estimate of$ 247.6 million.The company's shares lost almost 16% in after-market trading on Mar 6, likely due to the earnings miss ...